Resverlogix: Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

(marketscreener.com) Resverlogix Corp. announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. , extending the maturity date to May 13, 2026. In connection with the extension, Hepalink's conversion privileges have been eliminated and the interest rate has been amended...https://www.marketscreener.com/quote/stock/RESVERLOGIX-CORP-1411552/news/Resverlogix-Announces-Two-Year-Extension-of-Debenture-and-Elimination-of-Conversion-Privileges-46710248/?utm_medium=RSS&utm_content=20240513